ATE189526T1 - Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten - Google Patents

Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten

Info

Publication number
ATE189526T1
ATE189526T1 AT89912824T AT89912824T ATE189526T1 AT E189526 T1 ATE189526 T1 AT E189526T1 AT 89912824 T AT89912824 T AT 89912824T AT 89912824 T AT89912824 T AT 89912824T AT E189526 T1 ATE189526 T1 AT E189526T1
Authority
AT
Austria
Prior art keywords
polypeptide
amino acid
polypeptides
substituted
active domain
Prior art date
Application number
AT89912824T
Other languages
English (en)
Inventor
James A Wells
Brian C Cunningham
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE189526T1 publication Critical patent/ATE189526T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT89912824T 1988-10-28 1989-10-30 Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten ATE189526T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26461188A 1988-10-28 1988-10-28
US42806689A 1989-10-26 1989-10-26
PCT/US1989/004778 WO1990004788A1 (en) 1988-10-28 1989-10-30 Method for identifying active domains and amino acid residues in polypeptides and hormone variants

Publications (1)

Publication Number Publication Date
ATE189526T1 true ATE189526T1 (de) 2000-02-15

Family

ID=26950658

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89912824T ATE189526T1 (de) 1988-10-28 1989-10-30 Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten

Country Status (6)

Country Link
US (4) US5580723A (de)
EP (1) EP0397834B1 (de)
AT (1) ATE189526T1 (de)
CA (2) CA2001774C (de)
DE (1) DE68929151T2 (de)
WO (1) WO1990004788A1 (de)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688666A (en) * 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
CA2001774C (en) * 1988-10-28 2001-10-16 James A. Wells Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US6583115B1 (en) * 1989-10-12 2003-06-24 Ohio University/Edison Biotechnology Institute Methods for treating acromegaly and giantism with growth hormone antagonists
CA2087267A1 (en) * 1990-08-17 1992-02-18 Steven H. Bass Metal ion mediated receptor binding of polypeptide hormones
NZ260103A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin with alterations in the alpha-helix-1 region
US5310882A (en) * 1990-11-30 1994-05-10 American Cyanamid Company Somatotropins with alterations in the α-helix 3 region
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
CA2095633C (en) * 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5510459A (en) * 1991-01-17 1996-04-23 Zymogenetics, Inc. Glucagon antagonists
CA2100874A1 (en) * 1991-01-17 1992-07-18 Robert A. Smith Methods for detecting glucagon antagonists
US6429186B1 (en) 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
ATE196548T1 (de) 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5684136A (en) * 1992-05-18 1997-11-04 Genentech, Inc. Chimeric hepatocyte growth factor (HGF) ligand variants
DE69333950T2 (de) * 1992-05-18 2006-08-17 Genentech, Inc., South San Francisco Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden
SG54115A1 (en) 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US6335319B1 (en) * 1994-11-15 2002-01-01 Metabolic Pharmaceuticals, Inc. Treatment of obesity
US6475806B1 (en) 1995-06-07 2002-11-05 Praecis Pharmaceuticals, Inc. Anchor libraries and identification of peptide binding sequences
DK0851925T3 (da) * 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AU723494B2 (en) * 1996-02-13 2000-08-31 Jcr Pharmaceuticals Co., Ltd. Mutant human growth hormones and their uses
SE9601231D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Monoclonal antibody
US5945296A (en) * 1996-03-29 1999-08-31 Pharmacia & Upjohn Ab Monoclonal antibody
US6500660B1 (en) * 1996-11-27 2002-12-31 Université Catholique de Louvain Chimeric target molecules having a regulatable activity
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
SI1695985T1 (sl) * 1997-04-07 2011-06-30 Genentech Inc Postopki za tvorbo humaniziranih protiteles z naključno mutagenezo
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
GB2375765B (en) * 1997-11-14 2003-02-26 Kymed Gb Ltd Tagged growth hormone molecules
GB9723955D0 (en) 1997-11-14 1998-01-07 Generic Biolog Limited Improvements in or relating to detection of molecules in samples
US6274712B1 (en) * 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
IL140918A0 (en) 1998-07-27 2002-02-10 Genentech Inc Improved transformation efficiency in phage display through modification of a coat protein
DE69940383D1 (de) * 1998-10-21 2009-03-19 Chugai Pharmaceutical Co Ltd Verfahren zum screenen von verbindungen, die die produktion von entzündungszytokinen inhibieren
AU776672B2 (en) 1998-12-30 2004-09-16 Beth Israel Deaconess Medical Center Characterization of a calcium channel family
US7063959B1 (en) * 1998-12-30 2006-06-20 Beth Israel Deaconess Medical Center, Inc. Compositions of the SOC/CRAC calcium channel protein family
WO2000040715A2 (en) 1999-01-05 2000-07-13 Trustees Of Boston University Improved nucleic acid cloning
US20040005673A1 (en) 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
US8153400B1 (en) 1999-04-26 2012-04-10 Beth Israel Deaconess Medical Center, Inc. Nucleic acids encoding a mutT domain-containing polypeptide
US6946265B1 (en) * 1999-05-12 2005-09-20 Xencor, Inc. Nucleic acids and proteins with growth hormone activity
US7166573B1 (en) * 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
AU5632500A (en) 1999-06-30 2001-01-31 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
CA2393869A1 (en) * 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
SE0000837D0 (sv) 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
DE10016083A1 (de) * 2000-03-31 2001-10-18 Ingenium Pharmaceuticals Ag Nicht-menschliches Tiermodell für Wachstumsdefizienz und Defekte der Informationsverarbeitung oder der kognitiven Funktion und seine Verwendung
EP2275557A1 (de) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albuminfusionsproteine
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20020032154A1 (en) * 2000-06-07 2002-03-14 Peyman John A. Interferon-suppressing placental lactogen peptides
US7435562B2 (en) * 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US20030017552A1 (en) * 2000-07-21 2003-01-23 Jarrell Kevin A. Modular vector systems
JP4520631B2 (ja) * 2000-11-22 2010-08-11 松本油脂製薬株式会社 耐久透水性付与剤及びその繊維
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002092619A2 (en) 2001-05-14 2002-11-21 The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US20030087274A1 (en) * 2001-07-05 2003-05-08 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003018782A2 (en) 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
ATE541921T1 (de) * 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
EP1430113A2 (de) * 2001-09-18 2004-06-23 Stem Cell Therapeutics Inc. Wirkung von wachstumshormon und igf-1 auf neurale stammzellen und therapeutische anwendung
EP2990417A1 (de) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin-insulin-fusionsprotein
SI2336359T1 (sl) 2002-05-09 2016-08-31 The Brigham And Women's Hospital, Inc. 1L1RL-1 kot marker kardiovaskularne bolezni
CA2488441C (en) * 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
JP4783013B2 (ja) * 2002-07-30 2011-09-28 ステム セル セラピューティクス インコーポレイテッド 多能性神経幹細胞からの希突起神経膠細胞産生
CA2492442A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
US7611700B2 (en) * 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
JP2006517787A (ja) 2002-10-07 2006-08-03 ルートヴィヒ・インスティテュート・フォー・カンサー・リサーチ ポリペプチド
US20050079574A1 (en) * 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
US7396646B2 (en) * 2003-01-22 2008-07-08 Modular Genetics, Inc. Alien sequences
WO2004064482A2 (en) * 2003-01-22 2004-08-05 Modular Genetics, Inc. Alien sequences
EP1592786B8 (de) 2003-02-11 2012-03-21 Shire Human Genetic Therapies, Inc. Diagnose und behandlung von multiplen sulfatase-erkrankungen und anderen sulfatase-erkrankungen mit hilfe eines formylglycin bildenden enzyms
EP1651207A4 (de) 2003-06-12 2008-10-01 Univ Colorado Systeme und verfahren zur behandlung von entzündlichen und proliferativen erkrankungen und wunden des menschen mit fettsäure-stoffwechsel-hemmern und/oder glykolytischen hemmern
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
EP1711533B1 (de) 2004-01-14 2013-12-11 Ohio University Verfahren zur Herstellung von Peptiden/Proteinen in Pflanzen und dadurch hergestellte Peptide/Proteine
EP2368579A1 (de) 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Tranglutaminase vermittelte konjugation von peptiden.
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
WO2005077404A1 (en) * 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005118621A2 (en) * 2004-04-16 2005-12-15 Genentech, Inc. Omi pdz modulators
CA2573918A1 (en) 2004-04-19 2005-11-24 Ohio University Cross-linkable glycoproteins and methods of making the same
EP1789453A2 (de) * 2004-05-18 2007-05-30 Genentech, Inc. Haupthüllproteinvarianten des m13-virus zur c-terminalen und bi-terminalen anzeige eines heterologen proteins
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
EA200601793A1 (ru) * 2004-06-23 2007-02-27 Ю Эс Ви ЛИМИТЕД Химерный гормон роста человека, полученный из изоформы плаценты и гипофиза, и способы получения указанной химеры
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US8197817B2 (en) 2004-12-17 2012-06-12 Dana-Farber Cancer Institute, Inc. Regulation of mink in thymocytes and T lymphocytes
CN103520735B (zh) * 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
ATE542920T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Modifiziertes menschliches wachstumshormon
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
MX2007007591A (es) 2004-12-22 2007-07-25 Ambrx Inc Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
AU2006255122B2 (en) * 2005-06-03 2010-10-21 Ambrx, Inc. Improved human interferon molecules and their uses
NZ565294A (en) * 2005-08-18 2010-06-25 Ambrx Inc Compositions of tRNA and uses thereof
EP1928488A4 (de) * 2005-09-27 2009-07-22 Stem Cell Therapeutics Corp Regulierung der oligodendrozyten-vorläufer-zellproliferation mit prolactin
WO2007047342A1 (en) 2005-10-12 2007-04-26 Allergan, Inc. Assays of molecular or subcellular interactivity using depolarization after resonance energy transfer (daret)
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
JP5508716B2 (ja) * 2005-11-08 2014-06-04 アンブルックス，インコーポレイテッド 非天然アミノ酸、および非天然アミノ酸ポリペプチドを修飾するための促進剤
EP2339014B1 (de) * 2005-11-16 2015-05-27 Ambrx, Inc. Verfahren und Zusammensetzungen mit nichtnatürlichen Aminosäuren
US8957187B2 (en) 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
CN105384807A (zh) * 2005-12-14 2016-03-09 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
CA2643502A1 (en) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Dosing regimes for lh or hcg and epo for treatment of neurological disorders
ES2487637T3 (es) 2006-04-10 2014-08-22 Genentech, Inc. Moduladores de PDZ Disheveled
AR060871A1 (es) * 2006-05-09 2008-07-16 Genentech Inc Union de polipeptidos con supercontigos optimizados
JP5250548B2 (ja) 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体ｈ因子の標的化
CA2663083A1 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
CN106190983B (zh) * 2006-09-08 2019-05-28 Ambrx公司 用于脊椎动物细胞的杂合抑制tRNA
CN101511856B (zh) * 2006-09-08 2016-01-20 Ambrx公司 脊椎动物细胞中抑制因子trna的转录
US20100022454A1 (en) * 2006-10-03 2010-01-28 Novo Nordisk A/S Peptides with High Affinity for the Prolactin Receptor
HRP20120336T1 (hr) 2007-03-22 2012-05-31 Heptares Therapeutics Limited Receptori vezani na mutacije g-proteina i metode njihovog odabira
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
BRPI0721707A2 (pt) * 2007-05-17 2013-01-15 Genentech Inc estruturas de cristal de fragmentos de neuropilina e complexos de neuropilina-anticorpo
KR101656107B1 (ko) * 2007-11-20 2016-09-08 암브룩스, 인코포레이티드 변형된 인슐린 폴리펩티드 및 이의 용도
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
MX2010008632A (es) 2008-02-08 2010-08-30 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
EP2318029B1 (de) * 2008-07-23 2017-11-01 Ambrx, Inc. Modifizierte bovine g-csf-polypeptide und ihre verwendung
CN102112157B (zh) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 具有延长的体内效能的缀合蛋白
WO2010034015A2 (en) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
EP2342223B1 (de) 2008-09-26 2017-04-26 Ambrx, Inc. Modifizierte tiererythropoietinpolypeptide und anwendungen davon
NZ592249A (en) 2008-09-26 2013-03-28 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
EP2389389B1 (de) 2009-01-22 2015-04-15 Novo Nordisk Health Care AG Stabile Wachstumshormonverbindungen
MX2011010681A (es) 2009-04-10 2012-01-20 Ablynx Nv Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
PT2438087T (pt) 2009-06-05 2017-08-04 Ablynx Nv Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
SG181769A1 (en) 2009-12-21 2012-07-30 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
SI2525834T1 (sl) 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Rastni hormoni s podaljšano in vivo učinkovitostjo
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
CN103269720A (zh) 2010-07-22 2013-08-28 诺沃—诺迪斯克保健股份有限公司 生长激素缀合物
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP3572091B1 (de) 2010-08-17 2023-12-13 Ambrx, Inc. Modifizierte relaxinpolypeptide und deren verwendungen
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
EP2446898A1 (de) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Wachstumshormonen zur Verbesserung der Immunantwort bei immunsupprimierten Patienten
MX355128B (es) 2011-10-14 2018-04-06 Genentech Inc Péptidos inhibidores de bace1 y uso de los mismos para el tratamiento de enfermedades o trastornos neurológicos.
MX2014004027A (es) 2011-10-14 2014-04-30 Genentech Inc Activadores de zimogeno.
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
EP2981282B1 (de) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Wachstumshormonverbindungsformulierung
US10227390B2 (en) 2013-06-14 2019-03-12 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
SG11201702824UA (en) 2014-10-24 2017-05-30 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof
EP3757119A1 (de) * 2015-11-16 2020-12-30 Ubiprotein, Corp. Verfahren zur verlängerung der halbwertszeit eines proteins
EP3526248A4 (de) 2016-10-17 2020-07-08 Musc Foundation for Research Development Zusammensetzungen und verfahren zur behandlung von läsionen des zentralnervensystems
WO2018148419A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665160A (en) 1982-03-22 1987-05-12 Genentech, Inc. Novel human growth hormone like protein HGH-V encoded in the human genome
US4670393A (en) * 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
US4699897A (en) * 1983-06-04 1987-10-13 Amgen Biologically active peptides structurally related to regions within growth hormones
BG49718A3 (bg) 1983-07-15 1992-01-15 Bio- Technology General Corp Метод за получаване на полипептид със супероксиддисмутазна активност
US4888286A (en) * 1984-02-06 1989-12-19 Creative Biomolecules, Inc. Production of gene and protein analogs through synthetic gene design using double stranded synthetic oligonucleotides
US4732973A (en) * 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
US4665180A (en) * 1984-11-06 1987-05-12 Petrolite Corporation Substituted tetrahydropyrimidines and octahydrophenanthridines
US4655160A (en) * 1985-09-10 1987-04-07 David R. Ligh Deck box
AU615194B2 (en) * 1987-03-12 1991-09-26 Amgen, Inc. Bovine growth hormone analogs
DE3877300T2 (de) * 1987-04-02 1993-06-03 Genentech Inc Substratunterstuetzte katalyse.
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
CA2001774C (en) * 1988-10-28 2001-10-16 James A. Wells Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
AU723494B2 (en) 1996-02-13 2000-08-31 Jcr Pharmaceuticals Co., Ltd. Mutant human growth hormones and their uses

Also Published As

Publication number Publication date
DE68929151D1 (de) 2000-03-09
EP0397834A4 (en) 1992-10-28
CA2345497A1 (en) 1990-04-28
US6428954B1 (en) 2002-08-06
WO1990004788A1 (en) 1990-05-03
DE68929151T2 (de) 2000-07-20
CA2001774A1 (en) 1990-04-28
EP0397834B1 (de) 2000-02-02
US5955346A (en) 1999-09-21
CA2001774C (en) 2001-10-16
US6451561B1 (en) 2002-09-17
US5580723A (en) 1996-12-03
EP0397834A1 (de) 1990-11-22

Similar Documents

Publication Publication Date Title
ATE189526T1 (de) Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
Schally et al. The amino acid sequence of a peptide with growth hormone-releasing activity isolated from porcine hypothalamus
Hofmann et al. An approach to the targeted attachment of peptides and proteins to solid supports.
LU91015I2 (fr) Recombinate (Rurioctocog alfa) dans toutes ses formes couvertes par le brevet de base
DK150146C (da) Analogifremgangsmaade til fremstilling af somatostatinanaloge hepta- eller octapeptider eller salte eller complexer deraf
DE68905633D1 (de) Markierer der t-zelle aktivierung.
Martens et al. Biosynthesis of pairs of peptides related to melanotropin, corticotropin and endorphin in the pars intermedia of the amphibian pituitary gland
Sexton et al. Biologically active salmon calcitonin-like peptide is present in rat brain
Eipper et al. Amidation of joining peptide, a major pro-ACTH/endorphin-derived product peptide.
ES2090598T3 (es) Procedimiento de ensayo de proteinas de union de hormonas inmunofuncional mediado por ligando.
Goltzman et al. Metabolism and biological activity of parathyroid hormone in renal cortical membranes.
KR950700934A (ko) 미엘린 염기성 단백질의 펩타이드 단편을 이용하여 t세포의 증식을 억제하는 방법
ES2150495T3 (es) Ligandos de flt3 purificados de mamifero y agonistas y antagonistas de los mismos.
Tang et al. Age-related and diurnal changes in Met5-Enk-Arg6-Phe7 and Met5-enkephalin contents of pituitary and rat brain structures
FERRARA et al. β‐ENDORPHIN: RADIORECEPTOR BINDING ASSAY: Relative Potency of Synthetic Analogs with Various Chain Lengths
BULANT et al. Processing of thyrotropin-releasing hormone (TRH) prohormone in the rat olfactory bulb generates novel TRH-related peptides
Mallette Immunoreactivity of human parathyroid hormone (28-48): attempt to develop an assay for intact human parathyroid hormone
Vestling Insulin: HPLC mapping of protease digestion products: A biochemistry laboratory experiment
DE69131289D1 (de) Polypeptide mit einer aktivität des menschlichen dopaminergischen rezeptors, deren kodierende nukleinsäuresequenzen und verwendung dieser polypeptide
Vance et al. Additive Edman degradation to sequence small peptides
IT1242173B (it) Metodo di analisi quantitativa altamente sensibile di acidi biliari e composizione per la analisi quantitativa.
Hirs The chemistry of peptides and proteins
Nakagawa et al. Retro analogs related to oxytocin
Lewis Chemistry of prolactin
Igarashi et al. In vitro protein synthesis directed by R17 viral ribonucleic acid. III. A new assay method for cell-free protein synthesis based on a phenylthiohydantoin procedure

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time